House concurrent resolution recognizing the importance of public awareness of tardive dyskinesia

This bill is a non-binding resolution that formally recognizes the importance of public awareness about tardive dyskinesia, a movement disorder affecting approximately 600,000 Americans. The resolution highlights that the condition can result from long-term use of certain antipsychotic medications and is more common in older adults, those with substance use disorders, and postmenopausal individuals. It notes that symptoms can significantly impact daily activities like eating, writing, and sleeping, and acknowledges the FDA-approved medication Ingrezza as a treatment option. The bill directs the Secretary of State to send a copy of the resolution to a federal policy analyst in Washington, DC, but does not create new laws or funding.